Archiv verlassen und diese Seite im Standarddesign anzeigen : Profitieren am Nanotechboom!
Mit Harris & Harris <TINY> habe ich meine erste mittelfristige Position im NanotechBereich erworben. Zum Thema Nanotech muss ich wohl nichts genauer erläutern. Dies wird mE definitiv die Boombranche schlechthin des nächsten Jahrzehntes. Mit TINY habe ich eine Nanotechbeteiligungsgesellschaft erworben, die in Amerika mit akt. ca. 85 Mio. Dollar bewertet wird. Da sich das Börsenumfeld immer mehr bessert, rechne ich Mitte 2004 mit den ersten Börsengängen aus dem Harris-Portfolio. Danach dürfte Harris vor einer kompletten Neubewertung stehen...Auch der Chart sieht momentan sehr attraktiv aus. Man sollte aufgrund der Umsätze in Amerika ordern.
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/3m/t/tiny.gif
Hier übrigen alle meinen Favoriten im Nanotechbereich ( manche haben mehr, manche weniger mit der Materie zu tun ). Alle scheinen mir aber auf Sicht von 2-3 Jahren sehr interessant zu sein:
http://ichart.yahoo.com/b?s=NANX
http://ichart.yahoo.com/b?s=NANO
http://ichart.yahoo.com/b?s=NPCT.OB
http://ichart.yahoo.com/b?s=NGEN
http://ichart.yahoo.com/b?s=TINY
Nanopierce ist natürlich hochspekulativ, hat aber auch dementsprechende Wertsteigerungschancen...
Harris & Harris von einem Jahreshoch zum Nächsten! Zum Glück sind auch hier viele dabei. Vielleicht knacken wir hier schneller als manche erwarten die 10 $ Marke. Seit Empfehlung sind wir hier nun schon ca. 25 % vorne :D
Deutscher Kurs nun schon bei 7,9 zu 8,1 E. :!: Letzter 7,9 E. -> +16,18 % :D
Harris & Harris explodiert in Amerika trotz einer Wallstreet im Minus... :D
Taxe in Deutschland: 7,6 E. zu 7,9 E. :wink:
Harris&Harris mit neuen Jahreshochs. Der Chart sieht nun sehr attraktiv aus... :wink: Hier sollte man wie gesagt dabeisein, der Nanotechzug läuft langsam los.
Und ganz zum Schluss noch: Mittelfristige Nanotechspekualtion Harris & Harris nimmt den 4ten Anlauf auf das X-Jahreshoch -> so langsam ist es der charttechnische Widerstand weicher geworden...
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/2y/t/tiny.gif
Harris & Harris hat mir heute ca. 20 % eingebracht und notiert trotz schwacher Weltmärkte nahe am 3-Jahreshoch bei 9,49 $ :shock: :wink: :D
http://ichart.yahoo.com/b?s=TINY
Darüberhinaus haben sich die restlichen Nanotechspekulationen gut bis sehr gut geschlagen.
Nanotech-Aktien setzen zum Höhenflug an
Von Christian Kirchner, Handelsblatt
Die Nachricht schlug an der Börse Tokio ein wie eine Bombe: Der japanische Nanotech-Zulieferer Jeol Ltd. gab am vergangenen Donnerstag bekannt, mit Hilfe nanoporöser Elektroden einen Akku hergestellt zu haben, der die gleiche Leistung wie ein handelsüblicher Nickel-Hybrid- Akku aufweist, gleichzeitig aber deutlich leichter ist und sich binnen einer Minute aufladen lässt. Die Aktien schlossen seitdem an der Börse Tokio täglich Limit Up, das heißt, mit jeweils 15 % Tagesplus.
DÜSSELDORF. Gut für die Jeol-Aktionäre, gut aber auch für den Activest Lux Nanotech, dessen zweitgrößte Position Jeol ist. Zuletzt wurde es etwas ruhig um die Investmentidee Nanotechnologie und den ersten Branchenfonds in diesem Segment. Zu Unrecht: Der Fonds kletterte seit Jahresbeginn um 38 %. Auch Achim Backhaus vom unabhängigen Fondsbeobachter Feri Trust bescheinigt dem Fonds eine gute Performance. Unter den 103 von uns beobachteten Technologiefonds belegt der Activest Lux Nanotech bezogen auf das Jahr 2003 Rang 14. Das ist deutlich über dem Sektordurchschnitt.
Unter Nanotechnologie verstehen Wissenschaftler alle Prozesse, die die Strukturen von atomarer Größe bis zu 100 Nanometern nutzen. Zur Veranschaulichung: Ein Nanometer verhält sich zu einem Meter wie ein Apfel zur gesamten Erdkugel. Als Querschnitttechnologie kann sie dabei in beinahe allen industriellen oder beispielsweise auch medizinischen Anwendungsgebieten eingesetzt werden.
Dieser Umstand erschwert Investoren allerdings die Suche nach Investmentvehikeln, um von den Innovationen der Branche zu profitieren. Patrick Fuchs, Analyst der DZBank, bescheinigt der Nanotechnologie großes Potenzial, gibt aber zu bedenken dass die größte Forschungsarbeit im universitären Umfeld geleistet wird. Die meisten Unternehmen erzielen mit Nanotechnologie nur geringe Umsätze.
Lukrativ für Investoren ist eher der Kauf von Zulieferern, auf die alle Unternehmen angewiesen sind, die in der Nanotechnologie forschen, sagt Thiemo Lang, Manager des Activest Lux Nanotech. Daher hat er rund 40 % des Fondskapitals in Hersteller von Analyse- und Prozessmaschinen investiert, die für die Forschung benötigt werden.
Weltmarktführer auf diesem Gebiet ist Veeco Instruments. Die Aktien des Unternehmens haben sich seit Jahresbeginn mehr als verdoppelt. Veeco bedient mit seinen Produkten alle Endmärkte der nanotechnologischen Forschung. Auch Jeol stellt Elektronenmikroskope her. Die Entwicklungsergebnisse in Sachen Batterie kamen daher auch für Activest-Manager Lang eher überraschend. Der Gelsenkirchener Schlauchhersteller Masterflex versucht, Nanotechnologie für die Verbesserung der Eigenschaften von Polyurethan zu nutzen, das der Konzern für mikroskopisch feine Schläuche in der Medizin einsetzt.
Aber auch große Unternehmen setzen auf die neue Technik. So gab der Halbleiterhersteller ST Microelectronics vor einer Woche bekannt, mit Hilfe einer nanofeinen Oberflächenstruktur die Herstellungskosten von Solarzellen deutlich verringern zu können. Und IBM veräußerte jüngst sein Festplattengeschäft an Hitachi, um sich auf profitable Bereiche zu konzentrieren. Big Blue behielt aber das so genannte Millipede-Projekt: Dabei gelang es Forschern mit Hilfe der Nanotechnologie, einem Prototypen mit einer Datendichte von einer Billion Bits pro Quadratzoll herzustellen. Das ist genug, um 25 Millionen Buchseiten oder den Inhalt von 25 DVDs auf der Fläche einer Briefmarke zu speichern. Das Speichermedium soll 2005 marktreif sein.
Auch das Produkt von Activest hat bereits Nachahmer gefunden: Anfang September lancierte die Investmentgesellschaft Hauck & Aufhäuser mit dem H&A Lux DAC NanotechFonds bereits den zweiten deutschen Nanotech-Fonds.
HANDELSBLATT, Donnerstag, 09. Oktober 2003, 12:32 Uhr
Die Zahlen von HH2 wurden gestern in Amerika nicht besonders gut aufgenommen. Ich werde hier wenn ich Ansätze eines Bodenbildungsprozesses sehe erste Positionen nachkaufen...Nanotech bleibt für mich eine der Zukunftstechnologien.
Harris & Harris Group Reports Net Asset Value of $2.11 Per Share as of September 30, 2003
Wednesday October 15, 5:33 pm ET
NEW YORK--(BUSINESS WIRE)--Oct. 15, 2003--Harris & Harris Group, Inc. (NASDAQ/NMS SYMBOL: TINY - News) announced today that at September 30, 2003, its unaudited net asset value and net asset value per share (NAV) were $24,225,912 and $2.11, respectively.
Valuations of venture capital deals remain subdued, and the pace of investment by the venture capital industry as a whole has picked up only slightly from depressed levels, despite the recovery in the stock market. There continue to be ample venture capital investment opportunities in tiny technology. Although some deals are oversubscribed, venture capital in general, including tiny technology, remains, in our view, essentially a buyer's market. Because tiny technology enables so many different applications, it is difficult to generalize about the field. But in nanotechnology in particular, there is growing government and private funding of research and development, and there are continual scientific, technological and commercial developments. Notwithstanding all of this constructive activity, we are unaware of any privately held tiny technology companies that are currently preparing initial public offerings or that are negotiating to be purchased by larger corporations.
-0-
SUMMARY OF FINANCIAL RESULTS
----------------------------
September 30, 2003 June 30, 2003 December 31, 2002
(Unaudited) (Unaudited) (Audited)
Total Assets $34,392,032 $35,903,212 $35,951,969
Net Assets $24,225,912 $25,496,210 $27,256,046
Total Net Income
Tax Liability $585,749 $591,055 $1,527,000
Accrued Profit
Sharing $0 $1,523 $15,233
Net Asset Value
per Share $2.11 $2.22 $2.37
Shares Outstanding 11,498,845 11,498,845 11,498,845
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 12 initial private equity investments have been in tiny-technology enabled companies.
Harris & Harris Group is a Business Development Company with 11,498,845 common shares outstanding.
Harris & Harris Group Notes Two New Nanosys Partnerships
Monday October 20, 9:48 am ET
NEW YORK--(BUSINESS WIRE)--Oct. 20, 2003--Nanosys, Inc. (www.nanosysinc.com) announced today that it has entered into two new commercial partnerships. The first partnership is the launch of Phase I of a potential $7.2 million joint development project supported by the Defense Advanced Research Projects Agency (DARPA) with partners Sciperio Inc., the University of Texas at Dallas and Penn State University. The contract, managed through the Air Force Research Labs (AFRL), is for the development of a new semiconductor technology for the fabrication of high-performance, large-area electronic systems on flexible substrates. The second partnership is a multi-million dollar strategic development deal with In-Q-Tel, a private non-profit group funded by the Central Intelligence Agency.
Harris & Harris Group has invested $1,500,000 in Nanosys, Inc., its largest investment in a tiny-technology company to date. Nanosys is a rapidly growing advanced technology company focused on the development of nano-enabled systems. These systems incorporate novel and patent-protected nanostructures that integrate functional complexity directly into each individual nanoparticle, enabling the low-cost fabrication of high-value, high-performance applications in a broad range of industries.
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 12 initial private equity investments have been in tiny-technology enabled companies.
Harris & Harris Group, is a Business Development Company with 11,498,845 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at http://www.TinyTechVC.com.
Harris & Harris 5,95 E. -> TH -> + 4,39 %
Form 10-Q for HARRIS & HARRIS GROUP INC /NY/
--------------------------------------------------------------------------------
6-Nov-2003
Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The information contained in this section should be read in conjunction with our September 30, 2003 Consolidated Financial Statements and our year-end 2002 Consolidated Financial Statements and the Notes thereto.
Background and Overview
We incorporated under the laws of the state of New York in August 1981. In 1983, we completed an initial public offering and invested $406,936 in Otisville BioTech, Inc. ("Otisville"), which also completed an initial public offering later that year. In 1984, Charles E. Harris purchased a controlling interest in us, thereby also becoming the control person in Otisville. We then divested our other assets and became a financial services company, with the investment in Otisville as the initial focus of our business activity. We hired new management for Otisville, and Otisville acquired new technology targeting the development of a human blood substitute.
By 1988, we operated two insurance brokerages and a trust company as wholly-owned subsidiaries. In 1989, Otisville changed its name to Alliance Pharmaceutical Corporation ("Alliance"), and by 1990, we had completed selling our $406,936 investment in Alliance for total proceeds of $3,923,559.
In 1992, we sold our insurance brokerage and trust company subsidiaries to their respective managements and registered as an investment company under the 1940 Act, commencing operations as a closed-end, non-diversified investment company. In 1995, we elected to become a business development company subject to the provisions of Sections 55 through 65 of the 1940 Act. Throughout our corporate history, we have made early-stage venture capital investments in a variety of industries. In 1994, we made our first nanotechnology investment. Since August 2001, we have made initial investments exclusively in tiny technology, including our last 12 initial investments.
Since our investment in Otisville in 1983, we have made a total of 54 venture capital investments, including four private investments in public equities. We have sold 36 of these 54 investments, realizing total proceeds of $105,659,158 on our invested capital of $38,366,523. Sixteen of these 36 investments were profitable. The average and median holding periods for these 36 investments were 3.6 years and 3.2 years, respectively. At September 30, 2003, we valued the 18 venture capital investments remaining in our portfolio at $14,192,218, or 58.6 percent of our net assets, net of unrealized depreciation of $2,891,452. At September 30, 2003, the average and median holding periods for our 18 current venture capital investments are 2.6 years and 1. 6 years, respectively.
We have invested a substantial portion of our assets in private, development stage or start-up companies. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth, have little or no history of operations and are developing unproven technologies. At September 30, 2003, $14,192,218 or 58.6 percent of our net assets consisted of venture capital investments at fair value, net of unrealized depreciation of $2,891,452. At December 31, 2002, $12,036,077 or 44.2 percent of our net assets consisted of venture capital investments at fair value, of which net unrealized depreciation was $2,718,389. At December 31, 2001, $13,120,978 or 53.9 percent of our net assets consisted of venture capital investments at fair value, of which net unrealized appreciation was $1,215,444.
We value our investments each quarter at fair value as determined in good faith by our Valuation Committee within guidelines established by our Board of Directors in accordance with the 1940 Act. (See "Footnote to Consolidated Schedule of Investments" contained in "Consolidated Financial Statements.")
We have broad discretion in the investment of our capital. However, we invest primarily in illiquid equity securities of private companies. Generally, these investments take the form of convertible preferred stock, are subject to restrictions on resale and have no established trading market. Our principal objective is to achieve long-term capital appreciation. Therefore, a significant portion of our investment portfolio provides little or no current yield in the form of dividends or interest. We do earn interest income from fixed-income securities, including U.S. Government and Agency Obligations. The amount of interest income earned varies with the average balance of our fixed-income portfolio and the average yield on this portfolio and is not expected to be material to our results of operations.
General business and capital markets conditions in 2002 and 2003 have been adverse for the venture capital industry. There have been few opportunities to take venture capital-backed companies public or sell them to established companies. During this period, it has been difficult to finance venture capital- backed companies privately and in general, for venture capital funds themselves to raise capital.
We present the financial results of our operations utilizing accounting principles generally accepted in the United States for investment companies. On this basis, the principal measure of our financial performance during any period is the net increase/(decrease) in our net assets resulting from our operating activities, which is the sum of the following three elements:
(1) Net Operating Income / (Loss) - the difference between our income from interest, dividends, and fees and our operating expenses.
(2) Net Realized Gain / (Loss) on Investments - the difference between the net proceeds of dispositions of portfolio securities and their stated cost.
(3) Net Increase / (Decrease) in Unrealized Appreciation on Investments - the net change in the fair value of our investment portfolio.
Because of the structure and objectives of our business, we generally expect to experience net operating losses and seek to generate increases in our net assets from operations through the long term appreciation of our venture capital investments. We have in the past relied, and continue to rely, on proceeds from sales of investments, rather than on investment income, to defray a significant portion of our operating expenses. Because such sales are unpredictable, we attempt to maintain adequate working capital to provide for fiscal periods when there are no such sales.
Results of Operations
Three months ended September 30, 2003, as compared to the three months ended September 30, 2002
We had a net decrease in net assets resulting from operations of $1,270,298 in the three months ended September 30, 2003, compared to a net increase in net assets resulting from operations of $660,988 in the three months ended September 30, 2002. We had a net increase in net assets resulting from capital stock transactions of $0 in the three months ended September 30, 2003, compared to a net increase in net assets resulting from capital transactions of $5,665,970 in the three months ended September 30, 2002.
Investment Income and Expenses:
We had net operating losses of $572,346 and $479,433 for the three months ended September 30, 2003, and September 30, 2002, respectively. In the three months ended September 30, 2003, our larger net operating loss reflected a net increase to expenses primarily related to an increase in salaries and benefits offset by a decrease in professional fees.
Operating expenses were $602,958 and $556,846 for the three months ended September 30, 2003, and September 30, 2002, respectively. In the three months ended September 30, 2003, as compared with the three months ended September 30, 2002, salaries and benefits increased by $100,142 or 38.5 percent, primarily as a result of an additional employee, and as a result of mandatory retirement plan pension expense that is being amortized through December 31, 2004. In the three months ended September 30, 2003, as compared with the three months ended September 30, 2002, professional fees decreased by $61,626, or 51.0 percent, primarily as a result of a shift in the timing of the expenses associated with the preparation of our proxy statement.
Realized Gains and Losses on Portfolio Securities:
During the three months ended September 30, 2003, and September 30, 2002, we realized losses of $1,003,919 and gains of $252,750, respectively.
During the three months ended September 30, 2003, we realized net losses of $1,003,919, consisting primarily of a loss of $1,000,001 on the realized loss resulting from the bankruptcy of Kriton Medical, Inc. from which we did not receive any direct distribution. During the three months ended September 30, 2002, we realized a net gain of $252,750, consisting primarily of a gain of $553,666 from our partnership interest in PHZ Capital Partners L.P., offset by a realized loss of $360,249 on the sale of Schwoo, Inc. convertible bridge loans.
Unrealized Appreciation and Depreciation of Portfolio Securities:
Net unrealized depreciation on investments decreased by $302,467 or 9.5 percent during the three months ended September 30, 2003, from $3,179,750 at June 30, 2003, to $2,877,283 at September 30, 2003.
During the three months ended September 30, 2003, we recorded a net decrease of $288,871 in unrealized depreciation of our venture capital investments.
Nine Months ended September 30, 2003, as compared to the nine months ended September 30, 2002
We had a net decrease in net assets resulting from operations of $3,030,134 in the nine months ended September 30, 2003, and a net increase in net assets resulting from operations of $58,343 in the nine months ended September 30, 2002.
Investment Income and Expenses:
We had net operating losses of $1,883,795 and $1,690,384 for the nine months ended September 30, 2003, and September 30, 2002, respectively.
Operating expenses were $2,029,647 and $1,887,627 for the nine months ended September 30, 2003, and September 30, 2002, respectively. Operating expenses in the nine months ended September 30, 2003, as compared with the nine months ended September 30, 2002, changed primarily for the following reasons:
(1) Operating expenses for the nine months ended September 30, 2003, included no expense for employee profit-sharing, as compared with $248,765 in such expense for the nine months ended September 30, 2002.
(2) Salaries and benefits increased by $304,076 or 39.0 percent, primarily as a result of the addition of an employee and mandatory retirement plan pension expense that is being amortized through December 31, 2004.
(3) Rent expense increased by $39,583 or 30.5 percent as a result of expenses incurred during the transition period to our new office space.
Realized Gains and Losses on Portfolio Securities:
During the nine months ended September 30, 2003, we realized net losses of $975,347. During the nine months ended September 30, 2002, we realized net gains of $1,052,110.
During the nine months ended September 30, 2003, we realized a loss of $1,000,001 resulting from the bankruptcy of Kriton Medical, Inc. from which we did not receive any direct distribution.
During the nine months ended September 30, 2002, we realized net gains of $1,052,110 consisting primarily of $1,661,892 from our partnership interest in PHZ Capital Partners L.P., offset by a loss of $350,583 on the dissolution of Informio, Inc. and a loss of $360,249 on the sale of Schwoo, Inc. convertible bridge loans.
Unrealized Appreciation and Depreciation of Portfolio Securities:
Net unrealized depreciation on investments increased by $157,170 during the nine months ended September 30, 2003, from $2,720,113 at December 31, 2002, to $2,877,283 at September 30, 2003.
During the nine months ended September 30, 2003, we recorded a net increase of $173,063 in unrealized depreciation of our venture capital investments.
Financial Condition
Nine Months ended September 30, 2003
Our total assets and net assets were $34,392,032 and $24,225,912, respectively, at September 30, 2003, compared with $35,951,969 and $27,256,046 at December 31, 2002.
Net asset value per share ("NAV") was $2.11 at September 30, 2003, versus $2.37 at December 31, 2002. Our shares outstanding remained unchanged during the nine months ended September 30, 2003.
Significant developments in the nine months ended September 30, 2003, were an increase in bank loan payable of $7,609,500 and an increase in the value of our investment in U.S. Treasury obligations of $2,989,888.
The increase in the value of our venture capital investments, from $12,036,077 at December 31, 2002, to $14,192,218 at September 30, 2003, resulted primarily from our three new venture capital investments and three follow-on investments, partially offset by a net decrease in the value of our venture capital investments.
The following table is a summary of additions to our portfolio of venture capital investments during the nine months ended September 30, 2003:
New Investment Amount
Chlorogen, Inc. $ 525,900 NanoGram Devices Corporation $ 750,000 Nanosys, Inc. $1,500,000
Follow-on Investment
NanoOpto Corporation $ 62,500 Nanotechnologies, Inc. $ 169,718 Nantero, Inc. $ 323,000
----------
Total $3,331,118
==========
The following table summarizes fair value of our entire investment portfolio, as compared with its cost, at September 30, 2003, and December 31, 2002, and December 31, 2001:
September 30, December 31,
2003 2002 2001
Investments, at cost.... $35,510,134 $30,206,935 $37,714,285 Unrealized (depreciation) appreciation.......... (2,877,283) (2,720,113) 1,216,420
----------- ------------ -----------
Investments, at fair
value................. $32,632,851 $27,486,822 $38,930,705
=========== =========== ===========
_______________
The accumulated unrealized depreciation on investments net of
deferred taxes was $3,722,202 at September 30, 2003, $3,565,032
at December 31, 2002, and $323,624 at December 31, 2001.
The following table summarizes the fair value composition of our venture capital portfolio at September 30, 2003, December 31, 2002, and December 31, 2001:
Category September 30, December 31, December 31,
2003 2002 2001
Tiny Technology 56.0% 49.0% 9.3%
Other Venture
Capital Investments 44.0% 51.0% 90.7%
----- ----- -----
Total Venture
Capital Investments 100.0% 100.0% 100.0%
===== ===== =====
Liquidity and Capital Resources
Our primary sources of liquidity are cash, receivables and freely marketable securities, net of short-term indebtedness. Our secondary sources of liquidity are restricted securities of companies that are publicly traded. We currently have no restricted securities of companies that are publicly traded. Nine Months ended September 30, 2003
At September 30, 2003, and December 31, 2002, our total net primary liquidity was $11,154,675 and $16,508,057, respectively. On both of the corresponding dates, our secondary liquidity was $0, as we had no restricted securities of companies that are publicly traded. Our tertiary source of liquidity was our partnership interest in PHZ Capital Partners L.P., which was liquidated effective December 31, 2002. We received the final distribution of $786,492 from PHZ Capital Partners L.P. in the first quarter of 2003.
The decrease in our net primary sources of liquidity from December 31, 2002, to September 30, 2003, is primarily owing to: (1) payment of federal, state and local taxes; (2) investment in Chlorogen, Inc.; (3) investment in Nanosys, Inc.; (4) investment in NanoOpto Corporation; (5) investment in Nanotechnologies, Inc.; (6) investment in Nantero, Inc.; and (7) use of funds for net operating expenses.
At September 30, 2003, our liability for accrued employee profit sharing was $0, as compared with $15,233 at December 31, 2002, as a result of the payment of $15,233 for the 2002 profit sharing.
Our total net income tax liability decreased by $941,251, from $1,527,000 at December 31, 2002 to $585,749 at September 30, 2003, primarily as a result of federal, state and local tax payments made for income earned in 2002.
Critical Accounting Policies
Critical accounting policies are those that are both important to the presentation of our financial condition and results of operations and those that require management's most difficult, complex or subjective judgments. Our critical accounting policies are those applicable to the valuation of investments.
Valuation of Portfolio Investments
As a business development company, we invest primarily in illiquid securities including debt and equity securities of private companies. The investments are generally subject to restrictions on resale and generally have no established trading market. We value substantially all of our equity investments at fair value as determined in good faith by our Valuation Committee. The Valuation Committee, comprised of at least three or more independent Board members, reviews and approves the valuation of our investments within the guidelines established by the Board of Directors. Fair value is generally defined as the amount that an investment could be sold for in an orderly disposition over a reasonable time. Generally, to increase objectivity in valuing our assets, external measures of value, such as public markets or third party transactions, are utilized whenever possible. Valuation is not based on long-term work-out value, nor immediate liquidation value, nor incremental value for potential changes that may take place in the future.
Recent Developments
On July 22, 2003, the Board of Directors approved a resolution stating that we are committed to maintaining the privacy of our shareholders and to safeguarding their non-public personal information. Generally, we do not receive any non- public personal information relating to our shareholders, although some non-public personal information of our shareholders may become available to us. We do not disclose any non-public personal information about our shareholders or former shareholders to anyone, except as permitted by law or as is necessary in order to service shareholder accounts (for example, to a transfer agent or third party administrator). We restrict access to non-public personal information about our shareholders to our employees and to employees of our service providers and their affiliates with a legitimate business need for the information. We maintain physical, electronic and procedural safeguards designed to protect the non-public personal information of our shareholders.
RISK FACTORS
Investing in our common stock involves a number of significant risks relating to our business and investment objective. You should carefully consider the risks and uncertainties described below before you purchase any of our common stock. These risks and uncertainties are not the only ones we face. Unknown additional risks and uncertainties, or ones that we currently consider immaterial, may also impair our business. If any of these risks or uncertainties materialize, our business, financial condition or results of operations could be materially adversely affected. In this event, the trading price of our common stock could decline, and you could lose all or part of your investment.
Risks related to the companies in our portfolio.
Investing in small, private companies involves a high degree of risk and is highly speculative.
We have invested a substantial portion of our assets in privately held development stage or start-up companies. These businesses tend to lack management depth, to have limited or no history of operations and to have not attained profitability. Tiny technology companies are especially risky, involving scientific, technological and commercialization risks. Because of the speculative nature of these investments, these securities have a significantly greater risk of loss than traditional investment securities. Some of our venture capital investments are likely to be complete losses or unprofitable and some will never realize their potential. We have been and will continue to be risk seeking rather than risk averse in our approach to venture capital and other investments. Neither our investments nor an investment in our common stock is intended to constitute a balanced investment program.
We may invest in companies working with technologies or intellectual property which currently has few or no proven commercial applications.
Nanotechnology, in particular, is a developing area of technology, of which much of the future commercial value is unknown, difficult to estimate and subject to widely varying interpretations. There are as of yet relatively few nanotechnology products commercially available. The timing of additional future commercially available nanotechnology products is highly uncertain.
Our portfolio companies working with tiny technology may be particularly susceptible to intellectual property disputes.
Research and commercialization efforts in tiny technology are being undertaken by a wide variety of government, academic and private corporate entities. As additional commercially viable applications of tiny technology begin to emerge, ownership of intellectual property on which these products are based may be contested. Any dispute over the ownership of, or rights to, any of our portfolio companies' technologies or products would have a material adverse affect on that company's value and may have a material adverse effect on the value of our common stock.
Our portfolio companies may not be able to market their products successfully.
Even if our portfolio companies are able to develop commercially viable products, the market for new products and services is highly competitive, rapidly changing and especially sensitive to adverse general economic conditions. Commercial success is difficult to predict, and the marketing efforts of our portfolio companies may not be successful.
Unfavorable economic conditions could result in the inability of our portfolio companies to access additional capital, leading to financial losses in our portfolio.
Most of the companies in which we have made or will make investments are susceptible to economic slowdowns or recessions. An economic slowdown or adverse capital or credit market conditions may affect the ability of a company in our portfolio to raise additional capital from venture capital or other sources or to engage in a liquidity event such as an initial public offering or merger. Such conditions may lead to financial losses in our portfolio, which could have a material adverse effect on the value of our common stock.
If the technologies utilized by our portfolio companies are found to cause health or environmental risks it could have an adverse effect on the value of our portfolio and on the value of our common stock.
Our portfolio companies work with new technologies, which could have potential environmental and health impacts. Tiny technology in general and nanotechnology in particular are currently the subject of health and environmental impact research. If health or environmental concerns about tiny technology or nanotechnology were to arise, our portfolio companies may incur additional research, legal and regulatory expenses, might have difficulty raising capital or could be forced out of business. This would have an adverse effect on the value of our portfolio and on the value of our common stock.
Risks related to the illiquidity of our investments.
We invest in illiquid securities and may not be able to dispose of them when it is advantageous to do so, or ever.
Most of our investments are or will be equity or equity- linked securities acquired directly from small companies. These equity securities are generally subject to restrictions on resale or otherwise have no established trading market. The illiquidity of most of our portfolio of equity securities may adversely affect our ability to dispose of these securities at times when it may be advantageous for us to liquidate these investments. We may never be able to dispose of these securities.
Unfavorable economic conditions could impair our ability to engage in liquidity events.
Our business of making private equity investments and positioning our portfolio companies for liquidity events may be adversely affected by current and future capital markets and economic conditions. The public equity markets currently provide little opportunity for liquidity events, even for more mature technology companies than those in which we typically invest. The potential for public market liquidity could further decrease and could lead to an inability to realize potential gains or could lead to financial losses in our portfolio and a decrease in our revenues, net income and assets. Recent government reforms affecting stock markets, investment banks and securities research practices may make it more difficult for privately held companies to complete successful initial public offerings of their equity securities. Slowdowns in initial public offerings also have an adverse effect on the frequency and valuations of acquisitions of privately held companies. The lack of exit opportunities also has an adverse effect on the ability of privately held companies to raise capital.
Even if our portfolio companies complete an initial public offering, the returns on our investments may be uncertain.
When companies in which we have invested as private entities complete initial public offerings of their securities, these newly issued securities are by definition unseasoned issues. Unseasoned issues tend to be highly volatile and have uncertain liquidity, which may negatively affect their price. In addition, we are typically subject to lock-up provisions which prohibit us from selling our investment into the public market for specified periods of time after an initial public offering. The market price of securities that we hold may decline substantially before we are able to sell these securities. Most initial public offerings of technology companies are listed on the Nasdaq National Market. Recent government reforms of the Nasdaq National Market have made market making by broker-dealers less profitable, which has caused broker-dealers to reduce their market making activities, thereby making the market for unseasoned stocks less liquid.
Risks related to our company. -
Because there is generally no established market in which to value our investments, our Valuation Committee's value determinations may differ materially from the values that a ready market or third party would attribute to these investments.
There is generally no public market for the equity securities in which we invest. Pursuant to the requirements of the 1940 Act, we value substantially all of the equity securities in our portfolio at fair value as determined in good faith by the Valuation Committee of the Board of Directors within the guidelines established by the Board of Directors. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment pursuant to specified valuation principles and processes. We are required by the 1940 Act to value specifically each individual investment on a quarterly basis and record unrealized depreciation for an investment that we believe has become impaired. Conversely, we must record unrealized appreciation if we believe that the underlying portfolio company has appreciated in value. Without a readily ascertainable market value and because of the inherent uncertainty of valuation, the fair value that we assign to our investments may differ from the values that would have been used had a ready market existed for the investments, and the difference could be material. Any changes in estimated fair value are recorded in our consolidated statements of operations as a change in the "Net (decrease) increase in unrealized appreciation on investments."
Because we are a non-diversified company with a relatively concentrated portfolio, the value of our business is subject to greater volatility than the value of companies with more broadly diversified investments.
As a result of investing a greater portion of our assets in the securities of a smaller number of issuers, we are classified as a non-diversified company. We may be more vulnerable to events affecting a single issuer or industry and therefore subject to greater volatility than a company whose investments are more broadly diversified. Accordingly, an investment in our common stock may present greater risk to you than an investment in a diversified company.
We may be obligated to pay substantial amounts under our profit sharing plan.
Our employee profit-sharing plan requires us to distribute to our officers and employees 20 percent of our net realized income as reflected on our consolidated statements of operations for that year, less the non-qualifying gain, if any. These distributions may have a significant effect on the amount of distributions made to our shareholders, if any.
Approximately 36 percent of the fair value of our venture capital investment portfolio, as of September 30, 2003, is concentrated in one company, NeuroMetrix, Inc., which is not a tiny technology company.
At September 30, 2003, we valued our investment in NeuroMetrix, Inc., which is not a tiny technology company, at $5,075,426, which represents 35.8 percent of the fair value of our venture capital investment portfolio, or 21.0 percent of our net asset value. Any downturn in the business outlook of NeuroMetrix, Inc., or any failure of the products of NeuroMetrix, Inc. to receive widespread acceptance in the marketplace, would have a significant effect on our specific investment in NeuroMetrix, Inc. and the overall value of our portfolio.
Approximately 44 percent of the fair value of our venture capital investment portfolio, as of September 30, 2003, is not invested in tiny technology.
Although all 12 of our portfolio investments added since August 2001 have been in tiny technology companies, and although we consider 13 of the companies in our current equity investment portfolio to be tiny technology companies, at September 30, 2003, only 56.0 percent of the fair value of our venture capital investment portfolio, 32.8 percent of our net asset value, is invested in tiny technology companies, which may limit our ability to achieve our investment objective.
We are dependent upon key management personnel for future success.
We are dependent for the selection, structuring, closing and monitoring of our investments on the diligence and skill of our senior management and other key advisers. We utilize lawyers and outside consultants, including two of our directors, Dr. Kelly S. Kirkpatrick and Lori D. Pressman, to assist us in conducting due diligence when evaluating potential investments. There is generally no publicly available information about the companies in which we invest, and we rely significantly on the diligence of our employees and advisers to obtain information in connection with our investment decisions. Our future success to a significant extent depends on the continued service and coordination of our senior management team, and particularly depends on our Chairman and Chief Executive Officer, Charles E. Harris. The departure of any of our executive officers, key employees or advisers could materially adversely affect our ability to implement our business strategy. We do not maintain for our benefit any key man life insurance on any of our officers or employees.
We will need to hire additional employees as the size of our portfolio increases.
We anticipate that it will be necessary for us to add investment professionals with expertise in tiny technology to accommodate the increasing size of our portfolio. We may need to provide additional scientific, business or investment training for our hires. There is competition for highly qualified personnel, and we may not be successful in our efforts to recruit and retain highly qualified personnel.
The market for venture capital investments, including tiny technology investments, is highly competitive.
We face substantial competition in our investing activities from many competitors, including but not limited to private venture capital funds; investment affiliates of large industrial, technology, service and financial companies; small business investment companies; wealthy individuals; and foreign investors. Our most significant competitors typically have significantly greater financial resources than we do. Many sources of funding compete for a small number of attractive investment opportunities. Hence, we face substantial competition in sourcing good investment opportunities on terms of investment that are commercially attractive.
In addition to the difficulty of finding attractive investment opportunities, our status as a regulated business development company may hinder our ability to participate in investment opportunities or to protect the value of existing investments.
We are required to disclose on a quarterly basis the name and business description of our portfolio companies and the value of any portfolio securities. Most of our competitors are not subject to these disclosure requirements. Our obligation to disclose this information could hinder our ability to invest in some portfolio companies. Additionally, other current and future regulations may make us less attractive as a potential investor than a competitor not subject to the same regulations.
Our failure to make follow-on investments in our portfolio companies could impair the value of our portfolio.
Following an initial investment in a portfolio company, we may make additional investments in that portfolio company as "follow-on" investments, in order to: (1) increase or maintain in whole or in part our ownership percentage; (2) exercise warrants, options or convertible securities that were acquired in the original or subsequent financing; or (3) attempt to preserve or enhance the value of our investment. Recently, "pay to play" provisions have become common in venture capital transactions. These provisions require proportionate investment in subsequent rounds of financing in order to preserve preferred rights such as anti-dilution protection or to prevent preferred shares from being converted to common shares.
We may elect not to make follow-on investments or otherwise lack sufficient funds to make those investments. We have the discretion to make any follow-on investments, subject to the availability of capital resources. The failure to make follow-on investments may, in some circumstances, jeopardize the continued viability of a portfolio company and our initial investment, or may result in a missed opportunity for us to increase our participation in a successful operation, or may cause us to lose some or all preferred rights pursuant to "pay to play" provisions. Even if we have sufficient capital to make a desired follow-on investment, we may elect not to make a follow-on investment because we may not want to increase our concentration of risk, because we prefer other opportunities or because we are inhibited by compliance with business development company requirements or the desire to maintain our RIC tax status.
Bank borrowing or the issuance of debt securities or preferred stock by us to fund investments in portfolio companies or to fund our operating expenses would make our total return to common shareholders more volatile.
Use of debt or preferred stock as a source of capital would entail two primary risks. The first risk is that the use of debt leverages our available common equity capital, magnifying the impact on net asset value of changes in the value of our investment portfolio. For example, a business development company that uses 33 percent leverage (that is, $50 of leverage per $100 of common equity) will show a 1.5 percent increase or decline in net asset value for each 1 percent increase or decline in the value of its total assets. The second risk is that the cost of debt or preferred stock financing may exceed the return on the assets the proceeds are used to acquire, thereby diminishing rather than enhancing the return to common shareholders. To the extent that we utilize debt or preferred stock financing for any purpose, these two risks would likely make our total return to common shareholders more volatile. In addition, we might be required to sell investments, in order to meet dividend, interest or principal payments, when it may be disadvantageous for us to do so.
As provided in the 1940 Act and subject to some exceptions, we can issue debt or preferred stock so long as our total assets immediately after the issuance, less some ordinary course liabilities, exceed 200 percent of the sum of the debt and any preferred stock outstanding. The debt or preferred stock may be convertible in accordance with SEC guidelines, which may permit us to obtain leverage at more attractive rates. The requirement under the 1940 Act to pay, in full, dividends on preferred shares or interest on debt before any dividends may be paid on our common stock means that dividends on our common stock from earnings may be reduced or eliminated. An inability to pay dividends on our common stock could conceivably result in our ceasing to qualify as a RIC under the Code, which would be materially adverse to the holders of the common shares.
We are authorized to issue preferred stock, which would convey special rights and privileges to its owners.
We are currently authorized to issue up to 2,000,000 shares of preferred stock, under terms and conditions determined by our Board of Directors. Such shares would have a preference over our common stock with respect to dividends and liquidation. The statutory class voting rights of any preferred shares we would issue could make it more difficult for us to take some actions that may, in the future, be proposed by the Board and/or holders of common stock, such as a merger, exchange of securities, liquidation or alteration of the rights of a class of our securities if these actions were perceived by the holders of the preferred shares as not in their best interests. The issuance of preferred shares convertible into shares of common stock might also reduce the net income and net asset value per share of our common stock upon conversion. These effects, among others, could have an adverse effect on your investment in our common stock.
Loss of status as a RIC would reduce our net asset value and distributable income.
We currently qualify as a regulated investment company, or RIC, under the Code. As a RIC, we do not have to pay Federal income taxes on our income (including realized gains) that is distributed to our shareholders. Accordingly, we are not permitted under accounting rules to establish reserves for taxes on our unrealized capital gains. If we failed to qualify for RIC status, to the extend that we had unrealized gains, we would have to establish reserves for taxes, which would reduce our net asset value, net of a reduction in the reserve for employee profit sharing, accordingly. To the extent that we, as a RIC, were to decide to make a deemed distribution of net realized capital gains and retain the net realized capital gains, we would have to establish appropriate reserves for taxes upon making that decision.
We operate in a regulated environment.
We are subject to substantive SEC regulations as a business development company. Securities and tax laws and regulations governing our activities may change in ways adverse to our and our shareholders' interests, and interpretations of these laws and regulations may change with unpredictable consequences. Any change in the laws or regulations that govern our business could have an adverse impact on us or on our operations. Also, as business and financial practices continue to evolve, they may render the regulations under which we operate less appropriate and more burdensome than they were when originally imposed.
Quarterly results fluctuate and are not indicative of future quarterly performance.
Our quarterly operating results fluctuate as a result of a number of factors. These factors include, among others, variations in and the timing of the recognition of realized and unrealized gains or losses, the degree to which we and our portfolio companies encounter competition in our markets and general economic and capital markets conditions. As a result of these factors, results for any one quarter should not be relied upon as being indicative of performance in future quarters.
To the extent that we do not realize income or retain after-tax realized capital gains, we may have a greater need for additional capital to fund our investments and operating expenses.
As a RIC, we must annually distribute at least 90 percent of our investment company taxable income as a dividend and may either distribute or retain our realized net capital gains from investments. As a result, such earnings may not be available to fund investments. If we fail to generate net realized capital gains or to obtain funds from outside sources, it would have a material adverse effect on our financial condition and results of operations as well as our ability to make follow-on and new investments. Because of the structure and objectives of our business, we generally expect to experience net operating losses and rely on proceeds from sales of investments, rather than on investment income, to defray a significant portion of our operating expenses. Such sales are unpredictable and may not occur. In addition, as a business development company, we are generally required to maintain a ratio of at least 200 percent of total assets to total borrowings, which may restrict our ability to borrow to fund such requirements.
Investment in foreign securities could result in additional risks.
We currently have no investments in foreign securities. If we invest in securities of foreign issuers, we may be subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues. In addition, changes in government administrations or economic or monetary policies in the United States or abroad could result in appreciation or depreciation of our securities and could favorably or unfavorably affect our operations. It may also be more difficult to obtain and enforce a judgment against a foreign issuer. Any foreign investments made by us must be made in compliance with U.S. and foreign currency restrictions and tax laws restricting the amounts and types of foreign investments.
Forward-Looking Statements
The information contained herein contains certain forward- looking statements. These statements include the plans and objectives of management for future operations and financial objectives, portfolio growth and availability of funds. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors that could cause actual results and conditions to differ materially from those projected in these forward-looking statements are set forth herein. Other factors that could cause actual results to differ materially include the uncertainties of economic, competitive and market conditions, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that the assumptions underlying the forward-looking statements included herein are reasonable, any of the assumptions could be inaccurate and therefore there can be no assurance that the forward-looking statements included or incorporated by reference herein will prove to be accurate. Therefore, the inclusion of such information should not be regarded as a representation by us or any other person that our plans will be achieved.
Nanogen - hier schon öfters vorgestellt - gestern + 51 % :
http://ichart.yahoo.com/b?s=NGEN
http://chart.yahoo.com/c/1y/n/ngen.gif
Harris & Harrs gestern mit neuem 3 Jahreshoch bei 10,59 $ ! In diesem Bereich sollte man mE weiterhin investiert sein... :D
Nanophase gestern mit neuen Jahreshochs! Ich kann nur immer wieder betonen: Man sollte in der Nanotechbranche früh genug langfristig positioniert sein...
http://ichart.yahoo.com/b?s=NANX
http://chart.yahoo.com/c/1y/n/nanx.gif
Bei Nanometrics das gleiche Bild. Das geld liegt manchmal wirklich auf der Straße, wenn man Trends früh genug erkennt.
http://ichart.yahoo.com/b?s=NANO
http://chart.yahoo.com/c/1y/n/nano.gif
IBM meldet Erfolge in der Nanotechnologie
(tecCHANNEL.de, 08.12.2003 15:43) IBM-Forscher wollen bei der IEEE-Konferenz in Washington einen Durchbruch bei der Nanotechnologie vermelden. Es sei gelungen, mit selbst anordnenden Polymermolekülen eine Vorlage für die Lithographie zu entwickeln.Die Selbstanordnung eröffnet neue Möglichkeiten zur Strukturierung in kleineren Dimensionen, als es bisher möglich war, sagte IBM-Forscher T.C. Chen. Anders als Forchungszweige, die Polymer-Moleküle als Grundlage für die Schaltkreise selbst verwenden, benutzt IBM das selbst anordnende Molekülraster als eine Art Stempelwerkzeug bei der Lithographie von herkömmlichem Siliziumdioxid. Vorteil laut IBM: Techniken und Materialien der herkömmlichen Lithographie können verwendet werden.Nachdem der so entstandene Silizium-Abdruck weiterbehandelt wurde, bleibe ein Abbild der Polymerstruktur aus Silizium-Nanokristallen im Bereich von 20 Nanometern übrig. Von der Polymervorlage sei dann nichts mehr übrig, hieß es. IBM demonstriert auf dieser Webseite die Funktion des Verfahrens. Die Forschungsergebnisse sollen zudem bei der IEDM gezeigt werden.
Kursgewinne aller Orten im NanotechBereich:
Alleine mein hier immer wieder erwähntes Investment Harris&Harris konnte sich in den letzten 3 Wochen ungefähr verdoppeln ( Chart siehe unten -> seit Empfehlung sind wir hier nun bereits knapp 150 % auf Dollarbasis vorne ), auch die andere Empfehlungen haben sich zumindest verdoppelt. Insgesamt hat sich meine positive Einschätzung des gesamten NanotechSektors als richtig herausgestellt. Ich halte an meinen Kaufempfehlungen von September in Bezug auf alle hier aufgeführten Werte fest, zumal die Marktkapitalisierungen der einzelnen Werte noch immer im Bereich von lediglich 200 Mio. $ liegen. Der Sektor wird momentan wie erwartet ansatzweise entdeckt, die enormen Umsätze der letzten Wochen beweisen dies. Zum gegenwärtigen Zeitpunkt würde ich hier zwar nicht mehr zukaufen ( da die Werte extrem überkauft sind ), nach kleinen, gesunden Rückschlägen im Rahmen von 10 - 20 % werde ich hier weiterhin bestehende Positionen aufstocken.
Bestes Beispiel wie hoch der Nachholbedarf bei den von mir damals vorgestellten Nanotechwerten ist, zeigt der gestrige Handelstag. Der Dow verliert in der Sitzung 133 Punkte, meine Werte wie Harris & Harris ( + 10,6 % ), Nanogen ( + 12,5 % ), Nanometrics ( + 19,7 % ) und Nanophase ( + 18 % ) notieren allesamt zweistellig im Plus. Ich gebe nirgendwo auch nur ein Stück in diesem Sektor ab ( trotz der extrem überkauften Situation -> kurzfristig orientierte Anleger sollten mE aber zumindest Teilverkäufe auf diesem Niveau vornehmen ). Auch Tux UCA ist hier positiv zu erwähnen. Darüberhinaus danke ich Boardexperte für die Zuschrift, das HH2 nun durch das neue Investmentgesetz von der noch bis Ende 2003 erhobenen Strafsteuer befreit wurde.
Harris & Harris Schlusskurs 18,58 $ ( + 10,6 % ) , Erstempfehlung zu ca. 7 $ im September, Umsatz ca. 2,4 Mio Stück ( durchschnittlich sonst gut 200T ):
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/2y/t/tiny.gif
Nanogen SK 11,99 $ ( + 12,48 % ) , Erstempfehlung zu ca. 4,5 $ im September, Umsatz ca. 10 Mio Stück ( durchschnittlich sonst ca. 2,5 Mio. ):
http://ichart.yahoo.com/b?s=NGEN
http://chart.yahoo.com/c/1y/n/ngen.gif
Nanometrics SK 20,5 $ ( + 19,67 % ) , Erstempfehlung zu ca. 10 $ im September, Umsatz ca. 3 Mio. Stück ( durchschnittlich sonst knapp 400 T ) :
http://ichart.yahoo.com/b?s=NANO
http://chart.yahoo.com/c/1y/n/nano.gif
Nanophase SK 12,39 $ ( + 18 % ), Erstempfehlung zu gut 5 $ im September, Umsatz ca. 3 Mio. Stück ( durchschnittlich sonst ca. 300T ) :
http://ichart.yahoo.com/b?s=NANX
http://chart.yahoo.com/c/1y/n/nanx.gif
Insgesamt sprechen die herausragende Technologie, sehr gute Zahlen ( gestern von Nanometrics ), Charts auf AllTimeHigh, extrem auffällige Umsätze und positive Kommentare und eine Reihe von Kaufempfehlung für o.g. Nanotechwerte. Unser Einstieg im September kam dementsprechend noch genau zum rechten Zeitpunkt und vor dem Einstieg der Masse.
Auch die extrem spekulative Nanotechinvestmentmöglichkeit Nanopierce schloss gestern 9 % im Plus. Dieser Wert ist aufgrund des spekulativen Characters aber nicht so meine Sache, der Chart sieht nun aber sehr gut aus.
Harris & Harris Group Announces Daniel V. Leff to Join Company
Thursday January 15, 8:51 am ET
NEW YORK--(BUSINESS WIRE)--Jan. 15, 2004--Harris & Harris Group, Inc. (NASDAQ/NMS SYMBOL: TINY - News) announced today that Daniel V. Leff, Ph.D., has agreed to join the Company as Executive Vice President and Managing Director. Mr. Leff was most recently a Senior Associate with Sevin Rosen Funds in the firm's Dallas, Texas office. He will relocate to Los Angeles, California, where he will establish and head a West Coast office for Harris & Harris Group. In addition, he will be one of the Company's four decision makers with respect to all of its venture capital investments and will be involved in the Company's strategic direction along with the Company's other senior officers.
Prior to joining Sevin Rosen Funds, Mr. Leff worked for Redpoint Ventures in the firm's Los Angeles office. In addition, he previously held engineering, marketing and strategic investment positions with Intel Corporation. Mr. Leff received his Ph.D. degree from UCLA's Department of Chemistry and Biochemistry, where his thesis advisor was Professor James R. Heath (recipient of the 2000 Feynman Prize in Nanotechnology). Mr. Leff also received an MBA from The Anderson School at UCLA and a B.S. in Chemistry from the University of California, Berkeley.
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 12 initial private equity investments have been in tiny-technology enabled companies.
Harris & Harris Group is a business development company with 13,798,845 common shares outstanding.
Und die hier im September vorgestellten Nanotechwerte explodieren weiter. TINY hat den 150 % Anstieg schön auskonsolidiert. Bei den anderen Werten gab es noch nichtmal diese Konsolidierung. Die Charts kennen beinahe nur eine Richtung. Hoch :D
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/2y/t/tiny.gif
http://ichart.yahoo.com/b?s=NGEN
http://chart.yahoo.com/c/1y/n/ngen.gif
http://ichart.yahoo.com/b?s=NANO
http://chart.yahoo.com/c/1y/n/nano.gif
[http://ichart.yahoo.com/b?s=NANX
http://chart.yahoo.com/c/1y/n/nanx.gif
Harris gesten mit einem schönen Intradayreversal. Im Bereich 15-16,5 $ scheint sich nun ein tragfähiger Boden auszubilden. Nächstes Kursziel sollte die 20 $ Marke sein:
http://ichart.yahoo.com/b?s=TINY
Nasdaq fast 40 Punkte gestern im Minus und was macht meine Nanotechempfehlung Harris&Harris ? Sie schließt ca. 2 % im Plus. An dieser immensen relativen Stärke sieht man, wie hoch der Titel von institutioneller Seite gefragt ist. Selbst schwache Tage werden hier aggressiv zum Einsammeln genutzt. Als Kursziel sind weiterhin die AllTimeHighs bei 20,7 $ zu sehen :D
http://ichart.yahoo.com/b?s=TINY
Nanogen und Harris & Harris ebenfalls weiter vorbörslich hoch :D Die Meldung scheint die ganze Branche hochzuziehen. Ich werde in einem halben Jahr, wenn der Nanotechbereich weiter so gut läuft, eine normale Jahresperformance damit erzielen. Und das steuerfrei. :D
Wer hier mit mir seit September 2003 dabei ist, hat sehr gut verdient .
NANOPHASE TECH (NasdaqNM:NANX) Quote data by Reuters
Pre-Market (RTM/ECN): 10.30 $ -> + 1.93 ( + 23.06% ) :lol:
Meine mittelfristige Position ist dadurch ca 20 % vorbörslich vorne :D Auch meine anderen Nanotechs vorbörslich stark. Seit meinen Erstkäufen bin ich hier durch die Bank weiterhin ca. 100 % vorne. Für mich in dem Bereich aufgrund von Diversifikationsaspekten weiterhin am interessantesten : Harris & Harris...
Altana beteiligt sich an Nanophase Technologies
Wien,25-03-04
Der deutsche Pharma- und Spezialchemiekonzern Altana hat sich im Bereich Nanotechnologie mit einer Beteiligung an einer US-Firma verstärkt. Altana ist mit Nanophase Technologies eine exklusive Partnerschaft eingegangen und hat sich mit 7% an dem Unternehmen beteiligt.
Dabei habe der Konzern Aktien im Wert von 10 Mio. Dollar erworben, die zwei Jahre lang nicht gehandelt werden dürfen, heißt es. "Das ist für uns eine strategische Investition", sagte ein Altana-Sprecher. An eine weitere Aufstockung der Beteiligung sei derzeit nicht gedacht.
In der Partnerschaft mit dem US-Unternehmen will Altana Nanomaterialien herstellen, die etwa in Industrielacken, Fahrzeuglacken, Kunststoffen oder Elektroisolierstoffen eingesetzt werden. Unter Nanotechnologie wird die Entwicklung kleinster Strukturen in der Größenordnung von weniger als 100 Nanometern verstanden, mit denen etwa die Materialeigenschaften von Oberflächen und Beschichtungen entscheidend beeinflusst werden können.
Da sind andauernt schöne Sprünge drin... akt +24%
Wenn die Amis noch gut drauf sind, dann gehts noch mal hoch... Wow Tageshoch 8,5
Das Ding hat mir heut schon so viel eingebracht, wie die gesammte letzte Woche... :P
Neues von TINY:
Harris & Harris Group Invests in NeuroMetrix, Inc.
Thursday March 25, 11:02 am ET
NEW YORK--(BUSINESS WIRE)--March 25, 2004--Harris & Harris Group, Inc. announced today that it has invested $1.75 million as part of a $10 million follow-on placement of convertible preferred stock by privately held NeuroMetrix, Inc. (www.neurometrix.com). Harris & Harris Group was the seed investor in NeuroMetrix in 1996 and now owns approximately a fully diluted 12 percent interest in NeuroMetrix. Harris & Harris Group is the second largest shareholder in NeuroMetrix.
NeuroMetrix designs, manufactures and sells proprietary medical devices. NeuroMetrix's core technology is focused on utilizing non-invasively obtained data from nerves and muscles to perform an array of clinical diagnostic tests to detect and monitor carpal tunnel syndrome; to evaluate common causes of lower back pain, such as sciatica, as well as other neuromuscular conditions affecting the back and legs; and to evaluate diabetic neuropathy.
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 13 initial private equity investments have been in tiny-technology enabled companies. The Company has 13,798,845 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K and recent Prospectus filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.
--------------------------------------------------------------------------------
Contact:
Harris & Harris Group, Inc., New York
Charles E. Harris, 212-582-0900
Der größte Renner am gestrigen Handelstag war meine Spekulationen im Nanotechbereich! Harris & Harris mit SK 19,22 $ -> + 14,44 % Wie erwartet werden nun die AllTimeHighs bei gut 20 $ getestet. Die Umsätze waren gestern mit 3,2 Mio. Aktien überragend. Auch hier bin ich nun schon über 150 % vorne seit Erstkauf im September 03. Auch die anderen Nanos konnten gestern glänzen. Nach den optimal gelaufenen Brauerei- und Goldspekulationen ist dies die dritte groß angelegte Branchenspekulation , die vom Timing und von den Kursgewinnen optimal aufgeht.
TINY HARRIS & HARRIS 19.22 +14.4%
NANO NANOMETRICS 17.43 +13.9%
NGEN NANOGEN INC 9.35 +24.2%
NANX NANOPHASE TECH 11.16 +12.5%
NPCT.OB NANOPIERCE TECH 0.43 +26.5%
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/1y/t/tiny.gif
MTC (NoggerT)
03.04.2004, 13:14
Hallo Fredz,
Tiny hat sich gestern seht gut
geschlagen..bei den meisten
anderen Nanos gab' es Gewinn-
mitnahmen.
gruss & weiterhin viel Glück
bei Deiner Aktienauswahl :)
Hallo Fredz,
ist schon lustig, dass alles was Nano im Namen hat auch Nanotechnologie machen soll. Nanogen entwickelt med.-diagnostische Verfahren im Bereich Genanalyse. Hat eigentlich überhauptnichts mit sub-mikrometer Technolgie zu tun. Aber ist wohl eigentlich egal, hauptsache die Aktie steigt wenn sie soll!
Gruss
Hallo fredz,
Ab welche preis würdest Du TINY zukaufen? Bin auch schon eine welie dabai. Danke vorraus.
gruß arpad
MTC (NoggerT)
04.04.2004, 11:28
http://eur.i1.yimg.com/eur.yimg.com/i/de/fi/euroa2.gif
BOOM-AKTIEN - Abenteuer Nanotech (EurAmS)
Sie ist der neue Hype an den Börsen. Und tatsächlich bietet Nanotechnologie große Chancen. Doch längst nicht alles, was Nano heißt, ist auch super
Mitten in der Wüste von Nevada. Die Firma Xymos soll im Auftrag des US-Militärs Miniatur-Überwachungsanlagen bauen. Doch etwas läuft schief. Mutierte Mikroroboter entweichen durch ein Lüftungsrohr in die Wüste. Die Miniatur-Partikel entwickeln ein Eigenleben. Sie jagen Menschen und Tiere, um sie zu töten.
Nur eine Fiktion, gewiss. Erfunden von Bestsellerautor Michael Crichton. In seinem Thriller " Beute" sind es Nanopartikel, die außer Kontrolle geraten. In der Realität sind es Aktien von Unternehmen wie Nanophase Technologies, Altair Nanotechnologies oder Nanogen, die irrationale Bewegungen vollführen. Ende vergangenen Jahres haben sie sagenhafte Wertzuwächse verzeichnet - seit Januar2004 sind sie teilweise um 50 Prozent abgestürzt.
" Das sind Spielbälle von Spekulanten" , warnt Thiemo Lang, Manager des Fonds Activest Lux Nanotech. Und Marco Beckmann, Berater des Fonds Hauck & Aufhäuser Lux Dac Nanotech, fügt hinzu: " Viele Firmen, die Nano in ihrem Namen tragen, sind maßlos überbewertet."
Beispiel Nanogen. Das Unternehmen hat 2003 gerade mal 275000 Dollar (223000 Euro) umgesetzt, wird aber an der Börse mit 100 Millionen Euro bewertet. Oder Altair-Nanotechnologies. Die 21-Mitarbeiter-Firma stand vor wenigen Monaten noch vor der Pleite. Dann nahmen die Bosse den Zusatz Nano in die Firmenbezeichnung auf, und schon explodierte der Aktienkurs von 0,40 auf 3,80 Dollar. Der Marktwert liegt heute bei 150 Millionen Dollar.
Der Begriff Nanotechnologie elektrisiert die Anleger. Nicht ohne Grund. Die Nanotechnologie widmet sich den Grundbausteinen von Materialien, den Atomen. Durch Manipulationen der Strukturen ändern sich die Eigenschaften des Endprodukts radikal. Viele Wissenschaftler sehen in der extremen Miniaturisierung daher den Auslöser für eine neue industrielle Revolution. Die Investmentbank Merrill Lynch stellt die Nanotechnologie gar auf eine Stufe mit der Erfindung der Eisenbahn, des Autos und des Computers.
Bereits heute eröffnet die Nanotechnologie in der Materialwissenschaft neue Dimensionen. Nano-Röhren sind im Vergleich mit solchen aus Stahl 100 Mal zugfester, haben jedoch nur ein Sechstel des Gewichts. Autolacke sind hauchdünn, aber kratzfest. Speicherchips in Nanoformat können gewaltige Datenmengen fassen. Nanopartikel schützen die Haut vor Sonnenbrand. In der Phantasie der Forscher schwimmen sogar bereits kleine Nanoroboter durch menschliche Blutbahnen und setzen zielgenau Krankheitserreger außer Gefecht - ähnlich wie in dem Science-Fiction-Klassiker " Reise ins Ich" .
Kein Wunder, dass den Winzlingen auch wirtschaftlich wahre Wunder zugetraut werden. Das Marktpotenzial der Nanotechnologie wird von der amerikanischen National Science Foundation für 2010 auf eine Billion Dollar geschätzt. Fondsberater Beckmann schwelgt, dass aus kleinen Nanotech-Firmen in wenigen Jahren milliardenschwere Konzerne werden könnten.
Besonnenere Gemüter wie Thiemo Lang halten das für völligen Unsinn. " Die Summe von einer Billion Dollar bezieht sich auf die Endverbraucher, die Produkte erwerben, die in irgendeiner Form mit Nanotechnologie zu tun haben. Der Anteil der wirklichen Nanotech-Industrie ist wesentlich geringer."
Einig ist er sich jedoch mit anderen Experten, dass diese Schlüsseltechnologie großes Potenzial in sich birgt. Das hat auch die Politik bemerkt. Ende 2003 unterzeichnete US-Präsident George W. Bush den " 21st Century Nanotechnology Research and Development Act" , der der Branche bis 2008 Fördermittel von 3,7 Milliarden Dollar zusichert. Doch auch die Firmen in Europa müssen nicht darben. Sie können jährlich mit einer Milliarde Dollar an EU-Zuwendungen rechnen.
Da wollen auch die Anleger nicht außen vor bleiben. Allerdings ist die Auswahl der aussichtsreichen Titel schwierig. Da Nanotechnologie kein neues Produkt, sondern ein Herstellungsverfahren ist, das viele Branchen von der Biotechnologie über die Halbleiterindustrie bis zur Chemie umfasst, ist auch die Zahl der Unternehmen, die sich mit dieser Technologie befassen, sehr groß. So haben etablierte Konzerne wie General Electric, IBM, DuPont oder Degussa zwar erhebliche Nanotech-Aktivitäten. Im Verhältnis zum Gesamtumsatz machen diese Geschäfte aber nur einen geringen Prozentsatz aus.
Auch die einschlägigen Nanotech-Highflyer sind kaum etwas für Normalanleger. Diese Werte sind nicht nur Gegenstand von Spekulationen, auch die Geschäfte der Firmen stehen auf unsicheren Füßen. Altair oder Nanophase stellen lediglich Grundstoffe her - Produkte, die von anderen relativ einfach nachgemacht werden können.
Weitaus interessanter findet Activest-Mann Lang Unternehmen, die sich als Systemanbieter im Markt positionieren beziehungsweise die Werkzeuge herstellen, die die Arbeit im Nanotech-Bereich erst ermöglichen. Dazu zählt er die amerikanischen Zulieferer Veeco Instruments und Fei Company. Auch die japanische Jeol, die an neuartigen Batterien für Hybrid-Fahrzeuge arbeitet, sowie Analog Devices, die Beschleunigungssensoren für Airbags produziert, stehen hoch in seiner Gunst.
Experte Beckmann favorisiert unentdeckte Werte aus der zweiten Reihe. Aber auch etabliertere Firmen wie die amerikanische Headwaters hält er in seinem Depot. Das Unternehmen stellt Nano-Katalysatoren her, die eine Direktumwandlung von Kohle in Diesel ermöglichen. Bei einem Umsatz von 388 Millionen Dollar erwirtschaftete die Firma im vergangenen Jahr einen Nettogewinn von 36,6 Millionen Dollar. Wer das Investment in Einzelwerte scheut, kann unter drei Nanotech-Fonds auswählen. Neben dem im November 2002 ins Leben gerufenen Lux NanoTech und dem Hauck & Aufhäuser H&A Lux Dac Nanotech ist seit 10. März auch der Nate1 von First Trust Portfolios auf dem Markt. Allen drei Fonds ist gemeinsam, dass sie einen Großteil des Geldes in den USA investieren, wo die meisten Unternehmen der Branche zu finden sind. Dabei haben die Fondsmanager sowohl kleine, spekulative Werte im Depot, zur Absicherung aber auch etablierte Konzerne wie Corning, Samsung oder Dow Chemical.
Darüber hinaus gibt es einen Indexschein der New Yorker Investmentbank Punk Ziegel & Company. Das Papier bildet die Kursentwicklung von 15 Nanotech-Aktien ab. Ganz neu: ein Nanotech-Index von Merrill Lynch. Der orientiert sich an 25 Nano-Werten, die nach Ansicht von Lang jedoch teilweise hochspekulativ sind: " Die Branche wittert Morgenluft. Da wird möglicherweise ein IPO-Markt vorbereitet."
Doch auch ein Investment in die Nanotech-Fonds ist trotz deren bislang guter Perfomance mit größeren Risiken verbunden. Die Fonds rangieren sämtlich in der Kategorie Spekulativ. Nichtsdestotrotz gibt sich Optimist Beckmann überzeugt: " Nanotech-Fonds werden das große Finanzthema der nächsten Jahre sein."
Was ist Nanotech
Nano ist eine griechische Vorsilbe und heißt Zwerg. Nanopartikel bewegen sich in der Größenordnung von einem Millionstel Millimeter oder einem Milliardstel Meter.
Nanotechnologie ist kein neues Produkt, sondern eine Querschnittstechnologie, die alle wichtigen Wissenschaften vereint. Nano-T-Shirts nehmen keinen Schweiß mehr an. Auf Nano-Küchenoberflächen haftet kein Schmutz und bei Nano-Glasfenstern kann die Lichtdurchlässigkeit elektrisch geregelt werden. Auch in der Medizin verspricht die Nanotechnologie große Fortschritte. Ein Fernziel der Wissenschaftler ist es, aus einem Bestand chemischer Baustoffe sämtliche Produkte zu erschaffen - ob dieser Traum jemals Wirklichkeit wird, ist allerdings offen.
Hey, cool, hier ist ja neuerdings richtig was los. Danke, NoggerT, TINY ist echt eine Hammeraktie. Ist auch nicht zu Unrecht bei mir von den Nanos am höchsten gewichtet. :D
Hallo kcs!
Wer sagt denn , dass "alles was Nano im Namen hat auch Nanotechnologie machen soll" ? Habe ja im Sept. 03 am Anfang meines Threads hier darauf hingewiesen, dass "manche der hier vorgestellten Titel mehr, manche weniger mit Nanotech zu tun hat" ( s.u. ) -> krasser als bei Nanogen ist es ja bei Nanometrics. Die haben was mit Präzisionstechnik zu tun. Aber das Kürzel "NANO" wird halt gekauft. Das habe ich mir hierdurch zunutze gemacht. Und die Performance ist beeindruckend. Der Plan ist also aufgegangen.
In Deutschland gab es ja damals auch so ein Beispiel: Biodata -> der Biotechwert :lol: :wink:
Gruß Fredz
Hier übrigen alle meinen Favoriten im Nanotechbereich ( manche haben mehr, manche weniger mit der Materie zu tun ). Alle scheinen mir aber auf Sicht von 2-3 Jahren sehr interessant zu sein.
Hallo Fredz,
ist schon lustig, dass alles was Nano im Namen hat auch Nanotechnologie machen soll. Nanogen entwickelt med.-diagnostische Verfahren im Bereich Genanalyse. Hat eigentlich überhauptnichts mit sub-mikrometer Technolgie zu tun. Aber ist wohl eigentlich egal, hauptsache die Aktie steigt wenn sie soll!
Gruss
Schaut Euch diese HammerAktie an... Neue AllTimeHighs akt. markier, neues AllTimeHigh bei knapp 22 $ -> noch ein paar Cent, dann liege ich bei dem Titel 200% vorne. :D
Wie erwartet : Bei TINY werden die Alltimehighs angegriffen. Die 20 $ Marke ist geknackt. :D
http://ichart.yahoo.com/b?s=TINY
Bei meiner mittelfristigen Nanotechspekulation ( KK bei knapp 8 $ ) Harris & Harris wird es heute spannend. Hier könnten wir das alte ATH von gut 20,5 $ knacken. Ich bin mal gespannt. Die Umsätze der letzten Tage ( zw. 1 und 3 Mio Stück ) signalisieren einen möglichen Break...
http://chart.yahoo.com/c/1y/t/tiny.gif
Wahnsinn, der ganze Nanotechbereich boomt heute:
TINY HARRIS & HARRIS 21.93 +11.9%
NGEN NANOGEN INC 9.36 +7.3%
NANO NANOMETRICS 18.13 +4.1%
NANX NANOPHASE TECH 10.95 +3.3%
NPCT.OB NANOPIERCE TECH 0.43 +7.5%
NNBP.PK NANOBAC PHARM 0.725 +12.4%
Früh am morgen sind noch meine größten Gewinner vom gestrigen Tag zu nennen: Die Nanotechwerte. Ich habe hier im gesonderten Thread im mittelfristigen Forum bereits im Sept. 03 auf die hohen Gewinnchancen hingewiesen. Danach wurden die Titel von den breiten Medien in Dt. und USA entdeckt, alle Werte konnten mittlerweile zw. 100 % und gut 200% zulegen :D
TINY HARRIS & HARRIS 22.49 +14.7%
NGEN NANOGEN INC 9.33 +7.0%
NANO NANOMETRICS 18.85 +8.2%
NANX NANOPHASE TECH 10.97 +3.5%
Der absolute Highflyer in dem Bereich ist weiterhin die hier immer wieder vorgestellte Harris & Harris , die gestern unter enormen Umsätzen iHv ca. 2 Mio. Stück ( = ca. 50 Mio $ ) genau 1 Cent unter Tageshoch und damit AllTimeHigh bei 22,49 $ schließen konnte. In den Tagen meiner Erstempfehlung hatte der Wert gerademal knapp 200.000 Stück Umsatz im Durchschnitt. Ich werde auch hier meine Gewinne weiterhin laufen lassen, die Marktkapitalisierung von ca. 260 Mio $ lässt mE noch weitere Kurssteigerungen zu, und die IPO Welle im Nanotechbereich hat noch garnicht begonnen... :D
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/1y/t/tiny.gif
Harris & Harris Group Invests in Continuum Photonics
Tuesday April 6, 10:28 am ET
NEW YORK--(BUSINESS WIRE)--April 6, 2004--Harris & Harris Group, Inc.(NASDAQ: TINY - News) announced today that it has made a follow-on investment of $739,000 in privately held Continuum Photonics, Inc. (www.continuumphotonics.com), as part of a venture financing of more than $17.5 million led by JK&B Capital. The other largest investors in the round include Boston Millennia Partners, Prism Venture Partners, Flagship Ventures and Gainesborough LLC.
Continuum Photonics, Inc. is a supplier of advanced photonic switch products to the communications and test industries.
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 14 initial private equity investments have been in tiny-technology enabled companies. The Company has 13,798,845 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
Trotz der schwachen Nasdaq auch heute wieder eine schöne Überraschung. Harris&Harris mit neuem AllTimeHigh heute bei 23,6 $ :!: :!: :!: :D Die ersten 200% Gewinn sind eingefahren.
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/1y/t/tiny.gif
Momentan wird bei TINY das alte Ausbruchsniveau getestet. Charttechnisch gesund und absolut sauber. Ich bleibe hier trotz Gewinnen von ca. 200 % weiter investiert. Die Marktkapitalisierung lässt mE noch weitere größere Kurssprünge zu.
Mittelfristige Nanotechspekulation Harris&Harris ( KK um 7 $ ) gestern wieder mit kurzfristigen Kufsignalen. Der Chart ist nun mustergültig auskonsolidiert und mE bereit für neue AllTimeHighs:
http://ichart.yahoo.com/b?s=TINY
http://chart.yahoo.com/c/1y/t/tiny.gif
Nanotechs gestern trotz sehr guter Nasdaq eher schwach. Trotzdem konnte sich TINY als einer der wenigen Nanos ungefähr ausgeglichen aus der Sitzung verabschieden...
Freude haben in Amerika gestern nach 20 Uhr noch meine Nanotechs gemacht. Harris & Harris schloss sehr stark mit ca. 11 % im Plus und peilt die AllTimeHighs an.
http://ichart.yahoo.com/b?s=TINY
Auch die als Beimischung/ Diversifizierung gedachten anderen Nanotechs konnten sich größtenteils sehen lassen:
NNBP.PK NANOBAC PHARM 0.65 +18.2%
NGEN NANOGEN INC 7.93 +4.1%
NANO NANOMETRICS 14.58 +6.8%
NANX NANOPHASE TECH 8.85 +5.6%
NPCT.OB NANOPIERCE TECH -1.6%
AKC ACCESS PHARM 6.88 +4.2%
In den letzten Tagen hart umkämpft ist die wichtige 15 $ Marke bei TINY... Diese zu verteidigen ist von charttechnischer Bedeutung.
Mittelfr. Position wird nach dem Absacken heute morgen auf um die 9,5 E. nun Schritt für Schritt hochgetaxt :D Vorbörslich in USA nun nach ca. 6 % Minus dick im Plus.
Harris & Harris Group, Inc. Announces Follow-on Public Offering of 3,000,000 Shares of Common Stock at $11.25 Per Share
Wednesday June 30, 7:45 pm ET
NEW YORK--(BUSINESS WIRE)--June 30, 2004--Harris & Harris Group, Inc. (NASDAQ: TINY - News) today announced that it has priced a follow-on public offering of 3,000,000 shares of its common stock at a price of $11.25 per share for estimated net proceeds of approximately $31.7 million. The underwriters have a 30-day option to purchase up to 450,000 additional shares of its common stock from the company solely to cover over-allotments, if any. All of the shares of common stock are being offered by Harris & Harris Group pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. This offering is expected to close on July 7, 2004. ThinkEquity Partners LLC is acting as the lead manager for the offering. Punk, Ziegel & Company, L.P. is acting as a co-manager for the offering.
Harris & Harris Group intends to use the net proceeds of the offering to make new investments in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS) as well as follow-on investments in its existing venture capital investments, and for working capital.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A prospectus supplement relating to these securities has been filed with the Securities and Exchange Commission. This offering of the shares of common stock may be made only by means of the prospectus supplement and related prospectus, copies of which may be obtained from ThinkEquity Partners LLC, 28 West 44th Street, New York, NY 10036; Tel: (212) 869-7766, or Punk, Ziegel & Company, L.P., 520 Madison Avenue, New York, NY 10022; Tel: (212) 308-9494. For electronic copies please submit a request to os@i-deal.com.
About Harris & Harris Group (www.TinyTechVC.com)
Eine super Performance im Nanotechbereich gestern in Amerika. Wurde aber auch langsam Zeit nach den Kursverlusten der vergangenen Wochen -> besonders TINY sehr erfreulich:
Symbol Name Last Change
TINY HARRIS & HARRIS +13.66%
NANO NANOMETRICS +14.73%
NURO NEUROMETRIX +2.84%
NANX NANOPHASE TECH +3.63%
NGEN NANOGEN INC +5.03%
http://ichart.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.yahoo.com/z?s=TINY&t=1y&q=c&l=on&z=m&a=v&p=s
Harris & Harris Beteiligung Neurometrix gestern mit einer phantastischen Performance. Seit IPO haben die nun ca. 30 % gemacht. Auch TINY gestern mit einer guten Performance.
http://ichart.finance.yahoo.com/z?s=NURO&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=NURO&t=3m&q=c&l=on&z=m&a=v&p=s
MisterPresident
06.10.2004, 13:49
nach meinem 1. Kauf im Dez 2003 zu 6,30 , VK im Januar 04 mit über 100 % Gewinn . :wink:
Wiedereinstieg im August zu 6,28 , sehr wahrscheinlich werden es diesmal wieder 100 % :lol:
http://isht.comdirect.de/charts/big.chart?hist=1y&ind0=VOLUME&&lSyms=HH2.FSE&lColors=0x000000&sSym=HH2.FSE&hcmask=
Auchmeine mittelfr. Nanotechspekulation TINY gestern mit einer sehr schönen Performance. Ich spekuliere hier auf die alten Höchststände :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=3m&q=c&l=on&z=m&a=v&p=s
Gestern war Nanotechday in Amerika! Die einschlägigen Werte allesamt hoch. Meine langfristige Position TINY schließt mit 11,9 $ knapp 9 % im Plus. Das macht doch Freude :D Hier stehen kurzfristig neue charttechn. Kaufsignale an.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=3m&q=c&l=on&z=m&a=v&p=s
Mein Nanotechfavourit TINY gestern in den USA sehr stark und mit 12,3 $ fast 4 % vorne:
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=3m&q=c&l=on&z=m&a=v&p=s
Nanotechspekulation TINY geht ab :!: :D
Der Chart sieht sehr explosiv aus... :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=3m&q=c&l=on&z=m&a=v&p=s
Langfristige Nanotechspekulation TINY zum Handelsschluss mit sehr guten Umsätzen und Schluss auf TH bei 12,91 $ -> + 5,7 % :D Bis zu den Jahreshochs sind hier noch fast 10 $ zu verdienen... Der Wert bricht gerade charttechnisch aus. M.E. das beste Standbein, was man im Nanotechsektor haben kann.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://chart.finance.yahoo.com/c/3m/t/tiny.gif
TINY über 10 Euro -> letzter 10,1 E. -> TH -> + 7,1 % :D
Langfristige Nanotechspekulation Harris & Harris geht ab und erzeugt kurzfristige Kaufsignale... :D
Langfristige Nanotechspekulation TINY zum Handelsschluss mit sehr guten Umsätzen und Schluss auf TH bei 12,91 $ -> + 5,7 % :D Bis zu den Jahreshochs sind hier noch fast 10 $ zu verdienen... Der Wert bricht gerade charttechnisch aus. M.E. das beste Standbein, was man im Nanotechsektor haben kann.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://chart.finance.yahoo.com/c/3m/t/tiny.gif
Langfristige Nanotechspekulation Harris & Harris gestern mit einer sehr starken Performance und Schlusskurs am Tageshoch bei 13,85 $ -> + 4,92 % :D Hier hat es sich gelohnt trotz temporärer Schwäche dabeizubleiben / nachzukaufen. Der Wert dürfte mE bald wieder die alten Höchststände anpeilen, der Chart sieht sehr gut aus. Über 14 E. gibt es die nächsten Kaufsignale zu feiern. :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=6m&q=c&l=on&z=m&a=v&p=s
Der Widerstand bei 14 $ ist gebrochen :D
TINY weiter hoch, kein Wunder bei dem Chart :D
Langfristige Nanotechspekulation Harris & Harris gestern mit einer sehr starken Performance und Schlusskurs am Tageshoch bei 13,85 $ -> + 4,92 % :D Hier hat es sich gelohnt trotz temporärer Schwäche dabeizubleiben / nachzukaufen. Der Wert dürfte mE bald wieder die alten Höchststände anpeilen, der Chart sieht sehr gut aus. Über 14 E. gibt es die nächsten Kaufsignale zu feiern. :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=6m&q=c&l=on&z=m&a=v&p=s
Auch Harris&Harris heute sehr stark, der Break der 14 $ setzt neue Kräfte frei. Noch ein paar Cents, dann bin ich hier wieder 100 % vorne :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=6m&q=c&l=on&z=m&a=v&p=s
TINY 11,2 zu 11,39 Euro in FRA :D Wäre der Dollar nicht so schwach, würden wir hier bereits noch weitaus höher notieren.
nach meinem 1. Kauf im Dez 2003 zu 6,30 , VK im Januar 04 mit über 100 % Gewinn . :wink:
Wiedereinstieg im August zu 6,28 , sehr wahrscheinlich werden es diesmal wieder 100 % :lol:
http://isht.comdirect.de/charts/big.chart?hist=1y&ind0=VOLUME&&lSyms=HH2.FSE&lColors=0x000000&sSym=HH2.FSE&hcmask=
beim ersten run stand ich noch an der aussenlinie
diesmal bin ich dabei
eingestiegen wie mister president im august zu 6,48 euro :wink:
Hallo Schlutt!
Das nenne ich doch ein super Timing, Glückwunsch :!: :D Ich bin mal gespannt, ob wir in diesem Jahr noch die Jahreshochs über 20 $ angreifen, halte ich gut für möglich.
Gruß
nach meinem 1. Kauf im Dez 2003 zu 6,30 , VK im Januar 04 mit über 100 % Gewinn . :wink:
Wiedereinstieg im August zu 6,28 , sehr wahrscheinlich werden es diesmal wieder 100 % :lol:
http://isht.comdirect.de/charts/big.chart?hist=1y&ind0=VOLUME&&lSyms=HH2.FSE&lColors=0x000000&sSym=HH2.FSE&hcmask=
beim ersten run stand ich noch an der aussenlinie
diesmal bin ich dabei
eingestiegen wie mister president im august zu 6,48 euro :wink:
Nanotechspekulation TINY hat die 15 $ geknackt :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=1y&q=c&l=on&z=m&a=v&p=s
Im Nanotechbereich habe ich mir eine weitere Depotbeimischung im Nanobereich auf die WL genommen, der Chart sieht für mich recht attraktiv aus. In letzter Zeit beeindruckte der Wert unter verhältnismäßig guten Umsätzen mit einer sehr guten Performance. Über 9,2 E. mit neuen AllTimeHighs...
http://ichart.finance.yahoo.com/z?s=LMRA&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=LMRA&t=6m&q=c&l=on&z=m&a=v&p=s
Der gestern von mir hier vorgestellte Nanotechwert Lumera schloss nahe den Tageshöhen bei 8,45 $ -> + 9,46 %
Im Nanotechbereich habe ich mir eine weitere Depotbeimischung im Nanobereich auf die WL genommen, der Chart sieht für mich recht attraktiv aus. In letzter Zeit beeindruckte der Wert unter verhältnismäßig guten Umsätzen mit einer sehr guten Performance. Über 9,2 E. mit neuen AllTimeHighs...
http://ichart.finance.yahoo.com/z?s=LMRA&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=LMRA&t=6m&q=c&l=on&z=m&a=v&p=s
Die neuste Beteiligung von Harris & Harris ( s.u. ). Interessant auch: Auf jedem Kursniveau werden von den Insidern Aktien gekauft, null Verkäufe weit und breit zu sehen. Die Leute glauben an TINY so wie ich auch.
-> http://finance.yahoo.com/q/it?s=TINY
Harris & Harris Group Invests in Solazyme, Inc.
Tuesday November 30, 10:33 am ET
NEW YORK--(BUSINESS WIRE)--Nov. 30, 2004--Harris & Harris Group, Inc. announced today that it has invested $310,000 in Solazyme, Inc., as part of a larger funding round the company recently closed. Solazyme is a privately held company based in Menlo Park, California, and Daniel V. Leff, a Managing Director and Executive Vice President of Harris & Harris Group, Inc., has joined the Solazyme Board of Directors.
Solazyme is a biotechnology company devoted to harnessing the energy-harvesting machinery of photosynthetic microbes to produce valuable products including industrial chemicals, nutraceuticals and pharmaceuticals. The Company utilizes proprietary genetic engineering methods to develop commercially relevant, sunlight-driven biochemical pathways by exploiting microbial photosynthesis, a biochemical system benefiting from 2.5 billion years of evolutionary optimization yet brought to genomic light very recently.
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 19 initial private equity investments have been in tiny-technology enabled companies. The Company has 17,248,845 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
Hier mein absolutes Highlight gestern in Amerika: Langfristige Position Harris & Harris schloss unter gigantischen Umsätzen von ca. 1,5 Mio Stück :!: mit 12,5 % im Plus & auf TH :D Was für eine Trendumkehr nach gesunder Konsolidierung! Heute fällt uU die charttechn. Widerstandsmarke 14,8/15 $ :!:
Harris & Harris Group, In..
http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?minYear=631238400&sSymbol=TINY.NAS&sTimeframe=iD&sTimestamp=iD+iD+631238400http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?iInd0=na&iInd1=2&iInd2=na&iIndcount=1&iType=4&minYear=631238400&sAv1=na&sAv2=200&sAv2count=1&sBench1=na&sBench2count=1&sBenchcount=1&sMarket=TINY.NAS&sOrdType=price&sScale=linear&sSettings=na&sSymbol=TINY.NAS&sTimeframe=3M&sTimestamp=1095233400+1103009400+631238400
Auch meine Nanotechbeimischung Lumera steht charttechnisch vor der Entscheidung. Kerninvestment bleibt weiterhin die Harris & Harris.
LUMERA CORPORATION
http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?hiddenTimeFrame=1&iInd0=na&iInd1=2&iInd2=na&iIndcount=1&iType=1&minYear=1090540800&sAv1=na&sAv2=200&sAv2count=1&sBench1=na&sBench2count=1&sBenchcount=1&sInvSym=DJ.NYS&sMarket=LMRA.NAS&sOrdType=price&sScale=linear&sSettings=na&sSymbol=LMRA.NAS&sTimeframe=1Y&sTimestamp=1071473400+1103009400+1090540800
TINY hat die 15 $ erstmal geknackt, nach einer halben Stunde schon weit mehr als ein durchschnittlicher Tagesumsatz gehandelt :D
Hier mein absolutes Highlight gestern in Amerika: Langfristige Position Harris & Harris schloss unter gigantischen Umsätzen von ca. 1,5 Mio Stück :!: mit 12,5 % im Plus & auf TH :D Was für eine Trendumkehr nach gesunder Konsolidierung! Heute fällt uU die charttechn. Widerstandsmarke 14,8/15 $ :!:
Harris & Harris Group, In..
http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?minYear=631238400&sSymbol=TINY.NAS&sTimeframe=iD&sTimestamp=iD+iD+631238400http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?iInd0=na&iInd1=2&iInd2=na&iIndcount=1&iType=4&minYear=631238400&sAv1=na&sAv2=200&sAv2count=1&sBench1=na&sBench2count=1&sBenchcount=1&sMarket=TINY.NAS&sOrdType=price&sScale=linear&sSettings=na&sSymbol=TINY.NAS&sTimeframe=3M&sTimestamp=1095233400+1103009400+631238400
Harris&Harris 11,38 E. -> TH -> + 3,45 % :D
Harris & Harris geht weiter ab :D Der Break scheint nun nachhaltig zu sein! Nun rücken so langsam die alten Höchststände über 20 $ ins Visier.
Meine Nanotechspekulation Harris&Harris konnte gestern noch im Plus schließen und steht vor größeren charttechnischen Kaufsignalen. Ich bleibe hier weiter mit KK bei knapp 7 $ langfristig dabei. :D
TINY hat die 15 $ erstmal geknackt, nach einer halben Stunde schon weit mehr als ein durchschnittlicher Tagesumsatz gehandelt :D
Hier mein absolutes Highlight gestern in Amerika: Langfristige Position Harris & Harris schloss unter gigantischen Umsätzen von ca. 1,5 Mio Stück :!: mit 12,5 % im Plus & auf TH :D Was für eine Trendumkehr nach gesunder Konsolidierung! Heute fällt uU die charttechn. Widerstandsmarke 14,8/15 $ :!:
Harris & Harris Group, In..
http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?minYear=631238400&sSymbol=TINY.NAS&sTimeframe=iD&sTimestamp=iD+iD+631238400http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?iInd0=na&iInd1=2&iInd2=na&iIndcount=1&iType=4&minYear=631238400&sAv1=na&sAv2=200&sAv2count=1&sBench1=na&sBench2count=1&sBenchcount=1&sMarket=TINY.NAS&sOrdType=price&sScale=linear&sSettings=na&sSymbol=TINY.NAS&sTimeframe=3M&sTimestamp=1095233400+1103009400+631238400
Spitzenmäßig hat Haris & Harris gestern performed, die AKtie schloss am TH nur knapp unter 16 $ mit 1 Mio. Stück Umsatz ( nachbörslich bei 16 $ ). Der Grund für diese tolle Performance:
Harris & Harris Group Declares Deemed Dividend
Wednesday December 15, 4:57 pm ET
Harris & Harris geht weiter ab :D Der Break scheint nun nachhaltig zu sein! Nun rücken so langsam die alten Höchststände über 20 $ ins Visier.
Meine Nanotechspekulation Harris&Harris konnte gestern noch im Plus schließen und steht vor größeren charttechnischen Kaufsignalen. Ich bleibe hier weiter mit KK bei knapp 7 $ langfristig dabei. :D
TINY hat die 15 $ erstmal geknackt, nach einer halben Stunde schon weit mehr als ein durchschnittlicher Tagesumsatz gehandelt :D
Hier mein absolutes Highlight gestern in Amerika: Langfristige Position Harris & Harris schloss unter gigantischen Umsätzen von ca. 1,5 Mio Stück :!: mit 12,5 % im Plus & auf TH :D Was für eine Trendumkehr nach gesunder Konsolidierung! Heute fällt uU die charttechn. Widerstandsmarke 14,8/15 $ :!:
Harris & Harris Group, In..
http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?minYear=631238400&sSymbol=TINY.NAS&sTimeframe=iD&sTimestamp=iD+iD+631238400http://focus.comdirect.co.uk/_common/informer/lib/chart/middlechart.chart?iInd0=na&iInd1=2&iInd2=na&iIndcount=1&iType=4&minYear=631238400&sAv1=na&sAv2=na&sAv2count=1&sBench1=na&sBench2count=1&sBenchcount=1&sMarket=TINY.NAS&sOrdType=price&sScale=linear&sSettings=na&sSymbol=TINY.NAS&sTimeframe=3M&sTimestamp=1095404400+1103180400+631238400
Besonders erfreulich die Performance meiner langfristigen Position Harris & Harris ( KK um 6,8 $ ), die gestern wie auch viele andere Nanotechwerte mit 15,05 $ gut 5 % im Plus schloss! :D Nach der kleinen Zwischenkonsolidierung stehen die charttechnischen Zeichnen nun auf Grün, Kurse um das Jahreshoch über 20 $ scheinen mir kurzfristig möglich.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=2y&q=c&l=on&z=m&a=v&p=s
Langfr. Position Harris & Harris einer der Gewinner der Tage zw. Weihnachten & Neu Jahr. Der Chart sieht immer besser aus, schloss letzte Woche über 16 $...
Besonders erfreulich die Performance meiner langfristigen Position Harris & Harris ( KK um 6,8 $ ), die gestern wie auch viele andere Nanotechwerte mit 15,05 $ gut 5 % im Plus schloss! :D Nach der kleinen Zwischenkonsolidierung stehen die charttechnischen Zeichnen nun auf Grün, Kurse um das Jahreshoch über 20 $ scheinen mir kurzfristig möglich.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=2y&q=c&l=on&z=m&a=v&p=s
Nicht so erfreulich gestern die Performance von meinem Nanotechhighlight Harris & Harris! Der Wert schloss gut 8 % im Minus. Da ich hier aber mehr als 100% vorne liege, kann ich diese Zwischenkonsolidierungen gut aussitzen, nachbörslich ist der Titel auch schon wieder ein wenig ins Plus getaxt. Bei 14 $ lauert eine starker charttechn. Widerstand.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=6m&q=c&l=on&z=m&a=v&p=s
Mein langfristiges Investment Harris&Harris hat gestern seit langem auch mal wieder positiv performed, ein Plus von ca. 6 % stand zu Buche. Nach einer mustergültigen Konsolidierung, scheinen wir hier nun wieder das nachhaltige Reversal gesehen haben. Der SK lag auf Tageshoch, nachbörslich steigt der Wert weiter. :D
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=6m&q=c&l=on&z=m&a=v&p=s
schade, schade....
aber der aufwärtstrend ist dahin
mal schaun wie es weiter geht
8) 8) 8) 8) 8) 8) 8)
Hi Schlutt!
Nun siehts wieder gut aus um unsere TINY! Zudem mit knapp 80 % Kursgewinn im Buch kann man die kleinen Zwischenkonsolidierungen ja gut durchstehen.
Gruß
Langfristinvestment im Nanotechbereich Harris&Harris macht nach überstandener Konsolidierung seit Tagen wieder auf sich aufmerksam, am Freitag einer der Gewinner in den USA mit + 7 %. Die wiedererstarkte Dollar hebelt die ganze Spekulation momentan.
http://ichart.finance.yahoo.com/z?s=TINY&t=1d&q=c&l=on&z=m&a=v&p=s
http://ichart.finance.yahoo.com/z?s=TINY&t=6m&q=c&l=on&z=m&a=v&p=s
Hi Schlutt!
Nun siehts wieder gut aus um unsere TINY! Zudem mit knapp 80 % Kursgewinn im Buch kann man die kleinen Zwischenkonsolidierungen ja gut durchstehen.
Gruß
genau so ist es bin absolut relaxt,
solch eine konsolidierung ist wie die luft zum atmen....... :wink:
und momentan verliert der euro an boden
kommt uns hier zu gute :P
Genau so siehts aus: Was der Dollar uns in den letzten Aufwärtsbewegungen an Performance gekostet hat, legt er nun wieder drauf. :D
Tiny Is Beautiful: Translating 'Nano' Into Practical
By KENNETH CHANG
Published: February 22, 2005, New York Times
n the hip science of ultrasmall nanotechnology, fantastical future possibilities like rampaging nanorobots capture the most attention, but the first fruits of the field have been more mundane: tiny bits of mostly ordinary stuff that just sit there.
Yet these bits - nanoparticles - gain wondrous new capabilities simply because they are so small.
Advertisement
Nanoparticles of various sorts are already found in products like sunscreen, paint and inkjet paper. More exotic varieties offer promise in medicine for sensitive diagnostic tests and novel treatments: the detection of Alzheimer's disease by finding a protein in spinal fluid, for instance, or nanoparticles that heat up and kill cancer cells.
Some nanoparticles are not even on the cutting edge.
Medieval artisans unknowingly became nanotechnologists when they made red stained glass by mixing gold chloride into molten glass. That created tiny gold spheres, which absorbed and reflected sunlight in a way that produces a rich ruby color.
Nanotechnology, nanoparticles and all of the other nano words derive from nanometer, a billionth of a meter, or about one 25-millionth of an inch. That is far smaller than the world of everyday objects described by Newton's laws of motion, but bigger than an atom or a simple molecule, particles ruled by quantum mechanics.
A nanoparticle, an object with a width of a few nanometers to a few hundred, contains tens to thousands of atoms and exists in a realm that straddles the quantum and the Newtonian.
At those sizes, said Dr. Chad A. Mirkin, a director of Northwestern University's Institute for Nanotechnology, " everything, regardless of what it is, has new properties." And that, he added, is " where a lot of the scientific interest is."
This in-between realm gives rise to an unusual physics where the properties of a material change depending on its size. At the quantum level, one gold atom acts like any other gold atom, and a nugget of gold large enough to hold has the same chemical and electrical properties as another nugget. But two nanoparticles, both made of pure gold, can exhibit markedly different behavior - different melting temperature, different electrical conductivity, different color - if one is larger than the other.
" That creates a new way to control the properties of materials," said Dr. A. Paul Alivisatos, a professor of chemistry at University of California, Berkeley. " Instead of changing composition, you can change size."
Dr. Alivisatos works with nanoparticles known as quantum dots, made of semiconductors like silicon and gallium arsenide. The edges of the small particles influence the motion of electrons in the semiconductor, and the shape and size of quantum dots can be tailored to fluoresce specific colors. Current dyes used for lighting up protein and DNA fade quickly, but quantum dots could allow tracking of biological reactions in living cells for days or longer.
" They're just little rocks," Dr. Alivisatos said. He is a founding scientist of Quantum Dot Corporation, in Hayward, Calif., which is trying to turn the science into a business.
Other applications of nanoparticles take advantage of the fact that more surface area is exposed when material is broken down to smaller sizes. For magnetic nanoparticles, the lack of blemishes produces magnetic fields remarkably strong considering the size of the particles. Nanoparticles are also so small that in most of them, the atoms line up in perfect crystals without a single blemish.
Dr. David F. Kelley, a professor at the University of California, Merced, is making tiny disks exactly four atoms thick out of exotic semiconductors, which he hopes to stack together into solar cells. The disk shape reduces the space between particles, which should allow electrons to hop more easily between them. Because nanoparticles almost always contain flawless crystal structure, Dr. Kelley hopes that his nano solar cell will be more efficient at capturing light and turning it into electricity.
He plans more work on the basic properties of the disks before trying to connect everything together. " We will have a very good idea whether we can make this in the next year or two," he said.
For the medieval stained glass, the gold nanoparticles are simple spheres about 25 nanometers in diameter.
es gibt auch kritische Töne 8) Heftige Diskussion um Nanotechnologie
Andrea Naica-Lobell 09.02.2004
Teil I: Visionen und Horrorszenarien
Die potenziellen Risiken der Nanotechnologie rücken immer mehr in den Fokus öffentlicher Aufmerksamkeit. Es hat sich gezeigt, dass eigentlich harmlose Stoffe in Form winziger Partikel plötzlich giftig werden. Die Zukunfts-technologie, die vieles revolutionieren soll, steht im Kreuzfeuer der Kritik.
Die kritischen Stimmen gegen den Nanotechnologie-Hype ertönen schon seit Jahren und sie finden zunehmend Gehör in der Öffentlichk